Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04921241 · ClinicalTrials.gov registry record
In Utero Exposure to SARS-CoV-2 (COVID-19) and Cardiovascular and Metabolic Endpoints in Early Life
A clinical trial, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- 86
- Enrollment target
NCT04921241: Completed study, sponsored by Massachusetts General Hospital.
NCT04921241 is a clinical trial that has completed, run by Massachusetts General Hospital. The registered enrollment target is 86 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04921241 has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- 86 participants
- Enrollment target
Study Summary
Since its initial outbreak in late 2019, coronavirus disease 2019 (COVID-19) caused by the novel coronavirus SARS-CoV-2 has ravaged the globe, causing illness characterized by inflammation and impaired oxygen levels. As a particularly vulnerable group, pregnant women have had a heightened prevalence and severity of infection. In this context, a new population of children has emerged who were exposed to maternal COVID-19 in the womb. As maternal diseases during pregnancy may impact the health of offspring over the life course, health outcomes among these individuals must be urgently evaluated. In the current study, the investigators will leverage a perinatal biorepository comprised of pregnant women with and without COVID-19 to delineate the metabolic and cardiovascular risk profiles of these offspring. This work stands to benefit the burgeoning population of children exposed to COVID-19 in the womb and to deepen the mechanistic understanding of developmental origins of cardiometabolic disease with respect to maternal infections.
Interventions
- OTHER In Utero Exposure to SARS-CoV-2
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 86 participants |
| Start Date | 2021-06-08 |
| Est. Completion | 2024-01-01 |
What the finished NCT04921241 record still lists
NCT04921241 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 86 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which In Utero Exposure to SARS-CoV-2 is the first listed.
NCT04921241 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04921241 about?
NCT04921241 is a clinical study titled "In Utero Exposure to SARS-CoV-2 (COVID-19) and Cardiovascular and Metabolic Endpoints in Early Life". Since its initial outbreak in late 2019, coronavirus disease 2019 (COVID-19) caused by the novel coronavirus SARS-CoV-2 has ravaged the globe, causing illness characterized by inflammation and impaired oxygen levels. As a particularly vulnerable group, pregnant women have had a heightened prevalence...
What is the current status of trial NCT04921241?
This trial is currently completed. The enrollment target is 86 participants. The study started on 2021-06-08. Estimated completion is 2024-01-01.
What interventions are being tested in trial NCT04921241?
The interventions under investigation include: In Utero Exposure to SARS-CoV-2 (OTHER).
Who is sponsoring clinical trial NCT04921241?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01639508 · 86 participants · Phase 2
Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity
- NCT03519269 · 86 participants · NA
Navio Robotic Versus Conventional Total Knee Arthroplasty
- NCT04132999 · 86 participants · NA
PAP for Children With DS and OSAS
- NCT04545957 · 86 participants · NA
Jump: MR Simulation For Radiation Therapy Master Protocol
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI